title: Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.
abstract: Among several commonly used atypical antipsychotic drugs, olanzapine and risperidone cause a sensitization effect in the conditioned avoidance response (CAR) and phencyclidine (PCP)-induced hyperlocomotion paradigms--two well established animal tests of antipsychotic drugs, whereas clozapine causes a tolerance effect. Asenapine is a novel antipsychotic drug recently approved for the treatment of schizophrenia and manic disorders. It shares several receptor binding sites and behavioral features with other atypical antipsychotic drugs. However, it is not clear what type of repeated effect (sensitization or tolerance) asenapine would induce, and whether such an effect is transferrable to other atypicals. In this study, male adult Sprague-Dawley rats were first repeatedly tested with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) for avoidance response or PCP (3.20 mg/kg, sc)-induced hyperlocomotion daily for 5 consecutive days. After 2-3 days of retraining/drug-free recovery, they were then challenged with asenapine (0.10 mg/kg, sc), followed by olanzapine (0.50 mg/kg, sc) and clozapine (2.50 mg/kg, sc). During the 5-day drug test period (the induction phase), repeated asenapine treatment progressively increased its inhibition of avoidance response and PCP-induced hyperlocomotion in a dose-dependent fashion. On the asenapine and olanzapine challenge tests (the expression phase), rats previously treated with asenapine still showed significantly lower avoidance response and lower PCP-induced hyperlocomotion than those previously treated with vehicle. An increased reactivity to clozapine challenge in prior asenapine-treated rats was also found in the PCP-induced hyperlocomotion test. These findings suggest that asenapine is capable of inducing a sensitization effect and a cross-sensitization to olanzapine and clozapine (to a lesser extent). Because the behavioral profile of asenapine in both tests is similar to that of olanzapine, but different from that of clozapine, we suggest that asenapine resembles olanzapine to a greater extent than clozapine in its therapeutic and side effect profiles.
authors: Department of Neurology, The Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, PR China; Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE 68588-0308, USA.
authors: Rongyin
authors: R
authors: Qin
authors: Department of Neurology, The Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, PR China. Electronic address: yzchendr@gmail.com.
authors: Yingzhu
authors: Y
authors: Chen
authors: Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE 68588-0308, USA. Electronic address: mli@unl.edu.
authors: Ming
authors: M
authors: Li
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects*; D001569:Benzodiazepines / Q000494:pharmacology; D003024:Clozapine / Q000494:pharmacology; D003986:Dibenzocycloheptenes; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D006576:Heterocyclic Compounds, 4 or More Rings / Q000494:pharmacology*; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D000077152:Olanzapine; D010622:Phencyclidine / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D014150:Antipsychotic Agents; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings; D001569:Benzodiazepines; D010622:Phencyclidine; D003024:Clozapine; C522667:asenapine; D000077152:Olanzapine
keywords: Asenapine; Clozapine; Conditioned avoidance response; Locomotor activity; Olanzapine; Phencyclidine; Sensitization; Tolerance
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):414-22
references: 17945407
references: Psychopharmacology (Berl). 2008 May;198(1):103-11
references: 18297468
references: Pharmacol Biochem Behav. 2005 Aug;81(4):750-7
references: 15972234
references: Psychopharmacology (Berl). 2009 Nov;206(4):699-714
references: 19462162
references: Neuropsychopharmacology. 2007 Feb;32(2):263-72
references: 16738541
references: Psychopharmacology (Berl). 1997 Jan;129(1):79-84
references: 9122367
references: J Psychopharmacol. 2010 Mar;24(3):341-8
references: 18719049
references: Synapse. 2012 Jul;66(7):650-60
references: 22362425
references: Pharmacol Biochem Behav. 2013 Jan;103(3):467-73
references: 23026062
references: Eur Neuropsychopharmacol. 1999 Jan;9(1-2):165-70
references: 10082243
references: J Psychosoc Nurs Ment Health Serv. 2011 Apr;49(4):13-5
references: 21446639
references: Expert Opin Drug Discov. 2013 Jan;8(1):93-103
references: 23121334
references: J Psychopharmacol. 2009 Jan;23(1):65-73
references: 18308814
references: J Pharmacol Exp Ther. 2001 May;297(2):711-7
references: 11303062
references: Behav Brain Res. 2010 Dec 25;214(2):240-7
references: 20561963
references: Psychopharmacology (Berl). 2008 Feb;196(3):417-29
references: 17940749
references: Behav Pharmacol. 2009 Feb;20(1):84-98
references: 19179852
references: Behav Brain Res. 2013 Feb 1;238:178-87
references: 23092709
references: Psychopharmacology (Berl). 2010 Sep;212(1):45-57
references: 20623111
references: Pharmacol Biochem Behav. 2011 Mar;98(1):155-60
references: 21194545
references: Pharmacol Biochem Behav. 2012 Dec;103(2):174-80
references: 22960130
references: J Psychopharmacol. 2010 Jul;24(7):1045-53
references: 19329544
references: Synapse. 2006 Feb;59(2):92-100
references: 16270300
references: Eur J Pharmacol. 1995 Jul 4;280(2):R9-11
references: 7589172
references: Drugs Today (Barc). 2009 Dec;45(12):865-76
references: 20135021
references: Psychopharmacology (Berl). 2009 Jan;202(1-3):295-306
references: 18925388
references: Behav Pharmacol. 2012 Aug;23(4):380-91
references: 22732209
references: Nat Rev Drug Discov. 2009 Nov;8(11):843-4
references: 19876039
references: Int J Neuropsychopharmacol. 2010 Apr;13(3):405-10
references: 19835670
references: Eur J Pharmacol. 2009 Jan 14;602(2-3):334-42
references: 19059234
references: Naunyn Schmiedebergs Arch Pharmacol. 2007 Jun;375(4):261-71
references: 17458542
references: Neuropsychopharmacology. 2013 Feb;38(3):513-24
references: 23132270
references: Eur J Neurosci. 1999 Dec;11(12):4419-32
references: 10594669
references: Psychopharmacology (Berl). 2011 Apr;214(4):843-53
references: 21088957
references: Behav Pharmacol. 2012 Oct;23(7):658-68
references: 22903071
references: J Neural Transm (Vienna). 2012 Apr;119(4):497-505
references: 21986871
references: Clin Schizophr Relat Psychoses. 2012 Oct;6(3):134-44
references: 23006238
references: Neuropharmacology. 2012 Mar;62(3):1442-52
references: 21875607
references: Neuropsychopharmacology. 2008 Nov;33(12):2934-45
references: 18418367
references: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):175-82
references: 22476004
references: Behav Pharmacol. 2009 Mar;20(2):184-94
references: 19322074
references: Eur J Pharmacol. 2010 May 25;634(1-3):68-76
references: 20184878
references: J Pharmacol Exp Ther. 2003 May;305(2):625-31
references: 12606608
references: Eur J Pharmacol. 1995 Sep 5;283(1-3):55-62
references: 7498321
references: Synapse. 1999 Aug;33(2):118-28
references: 10400890
references: Behav Pharmacol. 2012 Feb;23(1):66-79
references: 22157143